scholarly journals The role of hepatitis B vaccine challenge dose in patients with underlying health conditions

2020 ◽  
pp. 1-5 ◽  
Author(s):  
L. Sticchi ◽  
I. G. Iavarone ◽  
P. Durando ◽  
A. Di Biagio ◽  
I. Schiavetti ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Hepatitis B Vaccine ◽  
Health Conditions ◽  
Challenge Dose

scholarly journals Circulating Tfh cell and subsets distribution are associated with low‐responsiveness to hepatitis B vaccination

2021 ◽  
Vol 27 (1) ◽  
Author(s):  
Mingjuan Yin ◽  
Yongzhen Xiong ◽  
Dongmei Liang ◽  
Hao Tang ◽  
Qian Hong ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Cellular Mechanisms ◽  
Immunological Responses ◽  
Follicular Helper ◽  
Low Responders ◽  
Specific Subset ◽  
Antibody Titers

Abstract Background An estimated 5–10 % of healthy vaccinees lack adequate antibody response following receipt of a standard three-dose hepatitis B vaccination regimen. The cellular mechanisms responsible for poor immunological responses to hepatitis B vaccine have not been fully elucidated to date. Methods There were 61 low responders and 56 hyper responders involved in our study. Peripheral blood samples were mainly collected at D7, D14 and D28 after revaccinated with a further dose of 20 µg of recombinant hepatitis B vaccine. Results We found low responders to the hepatitis B vaccine presented lower frequencies of circulating follicular helper T (cTfh) cells, plasmablasts and a profound skewing away from cTfh2 and cTfh17 cells both toward cTfh1 cells. Importantly, the skewing of Tfh cell subsets correlated with IL-21 and protective antibody titers. Based on the key role of microRNAs involved in Tfh cell differentiation, we revealed miR-19b-1 and miR-92a-1 correlated with the cTfh cell subsets distribution and antibody production. Conclusions Our findings highlighted a decrease in cTfh cells and specific subset skewing contribute to reduced antibody responses in low responders.

scholarly journals Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine

Hepatology ◽  
2018 ◽  
Vol 68 (3) ◽  
pp. 848-858 ◽  
Author(s):  
Nao Nishida ◽  
Masaya Sugiyama ◽  
Hiromi Sawai ◽  
Sohji Nishina ◽  
Aiko Sakai ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Hepatitis B Vaccine

Response to Challenge Dose Among Young Adults Vaccinated for Hepatitis B as Infants: Importance of Detectable Residual Antibody to Hepatitis B Surface Antigen

2015 ◽  
Vol 36 (5) ◽  
pp. 529-533 ◽  
Author(s):  
Philip R. Spradling ◽  
Saleem Kamili ◽  
Jian Xing ◽  
Jan Drobeniuc ◽  
Dale J. Hu ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Hepatitis B Vaccine ◽  
Immune Memory ◽  
Hepatitis B Vaccination ◽  
Challenge Dose ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

OBJECTIVETo determine whether a difference in antibody to hepatitis B surface antigen (anti-HBs) response to a hepatitis B vaccine challenge dose existed among persons with a baseline anti-HBs level of 0 mIU/mL (group 1) and those with “non-zero” levels of 0.1–4.9 (group 2) and 5.0–9.9 (group 3) mIU/mL, according to the VITROS ECi anti-HBs assay.DESIGNSubanalysis of randomized clinical trial. Response was defined as a postchallenge anti-HBs level of at least 10 mIU/mL and 4-fold rise in anti-HBs level 2 weeks after a single challenge dose of 10 vs 20 µg Engerix-B. Baseline was defined as the anti-HBs level immediately before administration of the challenge dose.SETTINGPediatric integrated healthcare system near Houston, Texas.PARTICIPANTSThree hundred nineteen US-born 16–19-year-olds who completed the hepatitis B vaccine series during the first year of life.RESULTSOne hundred seventy-eight persons had zero (group 1) and 141 (114 group 2 and 27 group 3) had non-zero anti-HBs levels at baseline. Response to the challenge dose was significantly higher among those with non-zero vs zero anti-HBs levels, irrespective of challenge dosage; only 1 person with a non-zero anti-HBs level failed to respond to the challenge dose (group 3, 27/27 [100%] vs group 2, 113/114 [99%] vs group 1, 145/178 [82%]; P<.0001).CONCLUSIONSAmong participants with residual anti-HBs levels less than 10 mIU/mL 16–19 years after primary hepatitis B vaccination during infancy, non-zero anti-HBs levels, with rare exception, indicated persistence of immune memory to HBsAg.TRIAL REGISTRATIONClinicalTrials.gov Identifier: NCT01341275Infect Control Hosp Epidemiol 2015;00(0):1–5

Role of T-regulatory cells in the response to hepatitis B vaccine in hemodialysis patients

2015 ◽  
Vol 20 (2) ◽  
pp. 242-252 ◽  
Author(s):  
Roy O. Mathew ◽  
Darius L. Mason ◽  
Renjie Song ◽  
Tiffany Tryniszewski ◽  
Jeffrey S. Kennedy
Keyword(s):  
Hepatitis B ◽  
T Regulatory Cells ◽  
Hemodialysis Patients ◽  
Hepatitis B Vaccine ◽  
Regulatory Cells

scholarly journals Impact of vaccination in the reduction of hepatitis B in Paraná

2014 ◽  
Vol 35 (1) ◽  
pp. 78-86 ◽  
Author(s):  
Priscila PUDELCO ◽  
Andreia Eloize KOEHLER ◽  
Lúcia Helena Linheira BISETTO
Keyword(s):  
Hepatitis B ◽  
Quantitative Research ◽  
Vaccine Coverage ◽  
Sexual Transmission ◽  
Secondary Data ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Role Of Nursing ◽  
The Impact

This study identified the impact of hepatitis B vaccine over reducing incidence of this disease in Paraná State, between 2001 and 2011, and discussed the role of nursing in immunization. Descriptive documental and quantitative research. Utilized secondary data of hepatitis B, between 2001 and 2011 and vaccination coverage of hepatitis B vaccine between 1995 and 2011 in Paraná State, available in DATASUS, SINAN and Immunization Programs. Data has been collected from May to July 2012. Included cases of hepatitis B confirmed by laboratory testing. Of the 14,434 selected cases, 81,8% was in urban residents, 86,5% belonged to 20 to 59 age group and 45,3% were infected by sexual transmission. In the correlation of vaccine coverage with the incidence, was identified reducing this rate in the range of 0 to 9 years old, in places with vaccination coverage's above 95%. It concludes that hepatitis B vaccination had impact over disease reduction in Paraná State.

Sign in / Sign up

Export Citation Format

Share Document